Zevra Therapeutics, Inc. (ZVRA) shareholders
Close on Nov 18, 2026Market cap $551.08MP/E 10.0Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (9.40%) | 5,562,781 | 9.40% | 13G (passive) amendment | Sep 30, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (8.30%) | 4,915,717 | 8.30% | 13G (passive) amendment | Jun 30, 2026 |
| Woodline Partners LP | 4,785,771 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 4,080,420 | 7.60% | 13G (passive) amendment | Dec 31, 2024 |
| Vanguard Capital Management | 3,024,980 | 5.11% | 13G (passive) | Jun 30, 2026 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (5.56%), Daniel Mack (5.56%) | 2,924,021 | 5.56% | 13G (passive) amendment | Sep 30, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ZVRA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,108,871 | 8.60% | $73.26M | +652,395 | 0.00% |
| FMR LLC | 4,915,717 | 8.28% | $70.49M | +1,703,840 | 0.00% |
| Woodline Partners LP | 4,785,771 | 8.06% | $68.63M | +1,334,828 | 0.21% |
| Nantahala Capital Management, LLC | 3,594,952 | 6.05% | $51.55M | +1,073,016 | 0.86% |
| Vanguard Capital Management LLC | 2,638,910 | 4.44% | $37.84M | +169,582 | 0.00% |
| State Street Corp | 1,681,999 | 2.83% | $24.12M | +120,430 | 0.00% |
| Geode Capital Management, LLC | 1,540,936 | 2.59% | $22.10M | +169,079 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,306,949 | 2.20% | $18.74M | +460,492 | 0.01% |
| Qube Research & Technologies Ltd | 1,241,343 | 2.09% | $17.80M | +399,024 | 0.02% |
| Morgan Stanley | 1,203,875 | 2.03% | $17.26M | +11,613 | 0.00% |
| Legal & General Group Plc | 1,201,668 | 2.02% | $17.23M | +38,578 | 0.00% |
| Dimensional Fund Advisors LP | 958,836 | 1.61% | $13.75M | +404,034 | 0.00% |
| Royce & Associates LP | 882,658 | 1.49% | $12.66M | −106,016 | 0.10% |
| 683 Capital Management, LLC | 855,000 | 1.44% | $12.26M | −120,000 | 0.60% |
| Kingdon Capital Management, L.L.C. | 775,000 | 1.31% | $11.11M | – | 1.14% |
| Retirement Planning Co of New England, Inc. | 634,410 | 1.07% | $9.10M | −16,738 | 3.27% |
| Jupiter Topco LLC | 613,403 | 1.03% | $8.80M | New | 0.00% |
| Arrowstreet Capital, Limited Partnership | 597,162 | 1.01% | $8.56M | New | 0.00% |
| Goldman Sachs Group Inc | 545,551 | 0.92% | $7.82M | −197,573 | 0.00% |
| Vanguard Portfolio Management LLC | 541,109 | 0.91% | $7.76M | +74,806 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 157 | 47M | 78.5% | 29 / 65 | 40 / 17 | 11M | 6M |
| Q1 2026 | 148 | 41M | 69.6% | 18 / 53 | 53 / 26 | 10M | 4M |
| Q4 2025 | 159 | 38M | 64.2% | 23 / 59 | 53 / 29 | 6M | 8M |
| Q3 2025 | 166 | 40M | 68.0% | 56 / 52 | 37 / 10 | 12M | 8M |
| Q2 2025 | 120 | 36M | 61.1% | 24 / 44 | 30 / 13 | 5M | 4M |
| Q1 2025 | 110 | 35M | 59.8% | 16 / 44 | 28 / 13 | 5M | 3M |
| Q4 2024 | 109 | 34M | 57.1% | 25 / 41 | 19 / 23 | 8M | 3M |
| Q3 2024 | 108 | 29M | 48.8% | 28 / 36 | 20 / 12 | 16M | 3M |
| Q2 2024 | 93 | 18M | 31.1% | 15 / 42 | 14 / 11 | 5M | 1M |
| Q1 2024 | 89 | 14M | 23.8% | 12 / 22 | 37 / 6 | 2M | 3M |
| Q4 2023 | 84 | 15M | 25.7% | 14 / 35 | 11 / 7 | 5M | 0M |
| Q3 2023 | 77 | 11M | 18.2% | 12 / 25 | 16 / 6 | 3M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
149 funds held ZVRA in Q2 2026, 47% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ZVRA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Contrafund | 2,943,298 | 4.96% | $42.21M | 0.02% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,899,706 | 3.20% | $27.24M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,524,549 | 2.57% | $21.86M | 0.03% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 679,907 | 1.14% | $9.75M | 0.01% | Jun 30, 2026 |
| Janus Henderson Small/Mid Cap Growth Alpha ETF | 670,077 | 1.13% | $6.37M | 0.61% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 644,248 | 1.08% | $6.13M | 0.02% | Jul 31, 2026 |
| Fidelity Contrafund K6 | 629,808 | 1.06% | $9.03M | 0.02% | Jun 30, 2026 |
| iShares Biotechnology ETF | 411,688 | 0.69% | $5.90M | 0.06% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 377,126 | 0.64% | $5.41M | 0.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 369,377 | 0.62% | $5.30M | 1.24% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 292,045 | 0.49% | $3.38M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 286,183 | 0.48% | $3.32M | 0.02% | May 31, 2026 |
| Royce Small-Cap Fund | 262,646 | 0.44% | $3.77M | 0.18% | Jun 30, 2026 |
| Janus Henderson Small Cap Growth Alpha ETF | 250,702 | 0.42% | $2.38M | 0.66% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 196,894 | 0.33% | $2.82M | 0.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Neil F. McFarlane | President and CEO, Director | 417,225 | 0.70% | Oct 13, 2026 |
| Rahsaan Thompson | Chief Legal & Compliance | 37,569 | 0.06% | Aug 17, 2026 |
| Timothy J. Sangiovanni | SVP, Finance & Corp Controller | 29,590 | 0.05% | May 29, 2026 |
| Justin A. Renz | CFO | – | – | Mar 19, 2026 |
| Joshua Schafer | CCO | 62,278 | 0.10% | Feb 4, 2026 |
| Adrian W. Quartel | Chief Medical Officer | 14,256 | 0.02% | Feb 2, 2026 |
| Corey Michael Watton | Director | 1,800 | 0.00% | Aug 12, 2026 |
| Thomas Anderson | Director | 20,000 | 0.03% | Jun 18, 2026 |
| Tamara A. Favorito | Director | 3,894 | 0.01% | Jun 18, 2026 |
| Alicia Secor | Director | – | – | Jun 18, 2026 |
| Alvin Shih | Director | 20,000 | 0.03% | Jun 18, 2026 |
| Douglas W. Calder | Director | – | – | Jun 18, 2026 |
| John B. Bode | Director | 123,400 | 0.21% | Mar 26, 2026 |
| Wendy L. Dixon | Director | – | – | May 30, 2025 |
| R. LaDuane Clifton | – | 192,028 | 0.32% | Jan 7, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Neil F. McFarlane President and CEO, Director | Oct 12, 2026 | Sale(10b5-1 plan) | −20,000 | $11.25 | $224.95K | 417,225 |
| Neil F. McFarlane President and CEO, Director | Oct 10, 2026 | Option exercise | +50,000 | – | – | 437,225 |
| Rahsaan Thompson Chief Legal & Compliance | Aug 14, 2026 | Sale(10b5-1 plan) | −42,666 | $11.13 | $474.87K | 37,569 |
| Corey Michael Watton Director | Aug 10, 2026 | Sale | −12,300 | $11.25 | $138.38K | 1,800 |
| Corey Michael Watton Director | Aug 10, 2026 | Option exercise | +12,300 | $4.97 | $61.13K | 14,100 |
| Rahsaan Thompson Chief Legal & Compliance | Jun 22, 2026 | Sale(10b5-1 plan) | −34,557 | $12.68 | $438.18K | 80,235 |
| Rahsaan Thompson Chief Legal & Compliance | Jun 21, 2026 | Option exercise | +66,667 | – | – | 114,792 |
| Rahsaan Thompson Chief Legal & Compliance | May 11, 2026 | Sale(10b5-1 plan) | −1,794 | $11.30 | $20.27K | 48,125 |
| John B. Bode Director | Mar 24, 2026 | Option exercise | +39,200 | $4.89 | $191.69K | 123,400 |
| John B. Bode Director | Mar 24, 2026 | Option exercise | +39,200 | $4.97 | $194.82K | 84,200 |
| Neil F. McFarlane President and CEO, Director | Feb 9, 2026 | Sale(10b5-1 plan) | −14,625 | $8.56 | $125.19K | 387,225 |
| Neil F. McFarlane President and CEO, Director | Feb 7, 2026 | Option exercise | +37,500 | – | – | 401,850 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Feb 3, 2026 | Sale(10b5-1 plan) | −3,000 | $9.18 | $27.54K | 29,590 |
| Joshua Schafer CCO | Feb 3, 2026 | Sale(10b5-1 plan) | −10,500 | $9.19 | $96.50K | 62,278 |
| Neil F. McFarlane President and CEO, Director | Feb 2, 2026 | Sale(10b5-1 plan) | −91,000 | $9.38 | $853.58K | 364,350 |
| Joshua Schafer CCO | Jan 31, 2026 | Option exercise | +35,334 | – | – | 72,778 |
| Neil F. McFarlane President and CEO, Director | Jan 31, 2026 | Option exercise | +233,334 | – | – | 455,350 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Jan 31, 2026 | Option exercise | +11,666 | – | – | 32,590 |
| Joshua Schafer CCO | Jan 30, 2026 | Sale(10b5-1 plan) | −3,375 | $8.83 | $29.80K | 37,444 |
| Joshua Schafer CCO | Jan 30, 2026 | Option exercise | +11,333 | – | – | 40,819 |
| Rahsaan Thompson Chief Legal & Compliance | Jan 30, 2026 | Option exercise | +11,333 | – | – | 53,999 |
| Rahsaan Thompson Chief Legal & Compliance | Jan 30, 2026 | Sale(10b5-1 plan) | −4,080 | $8.83 | $36.03K | 49,919 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Jan 30, 2026 | Option exercise | +6,333 | – | – | 22,674 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Jan 30, 2026 | Sale(10b5-1 plan) | −1,750 | $8.82 | $15.44K | 20,924 |
| Adrian W. Quartel Chief Medical Officer | Jan 30, 2026 | Option exercise | +11,333 | – | – | 14,256 |
| Adrian W. Quartel Chief Medical Officer | Jan 30, 2026 | Sale(10b5-1 plan) | −4,533 | $8.83 | $40.03K | 9,723 |
| R. LaDuane Clifton – | Dec 31, 2025 | Option exercise | +140,667 | – | – | 192,028 |
| R. LaDuane Clifton – | Dec 31, 2025 | Tax withholding | −48,513 | $8.96 | $434.68K | 143,515 |
| Neil F. McFarlane President and CEO, Director | Oct 10, 2025 | Sale(10b5-1 plan) | −19,500 | $10.82 | $210.99K | 222,016 |
| Neil F. McFarlane President and CEO, Director | Oct 10, 2025 | Option exercise | +50,000 | – | – | 241,516 |
| Tamara A. Favorito Director | Sep 12, 2025 | Buy | +3,175 | $7.79 | $24.73K | 3,894 |
| Alvin Shih Director | Sep 12, 2025 | Buy | +20,000 | $7.89 | $157.80K | 20,000 |
| John B. Bode Director | Aug 19, 2025 | Buy | +5,000 | $9.17 | $45.85K | 45,000 |
| Rahsaan Thompson Chief Legal & Compliance | Jun 26, 2025 | Sale(10b5-1 plan) | −24,000 | $9.21 | $221.04K | 42,666 |
| Rahsaan Thompson Chief Legal & Compliance | Jun 21, 2025 | Option exercise | +66,666 | – | – | 66,666 |
| Corey Michael Watton Director | Mar 28, 2025 | Buy | +300 | $7.84 | $2.35K | 1,800 |
| John B. Bode Director | Mar 19, 2025 | Buy | +10,000 | $7.96 | $79.60K | 40,000 |
| Neil F. McFarlane President and CEO, Director | Feb 14, 2025 | Sale(10b5-1 plan) | −30,544 | $8.05 | $245.88K | 191,516 |
| Neil F. McFarlane President and CEO, Director | Feb 13, 2025 | Sale(10b5-1 plan) | −61,273 | $7.86 | $481.61K | 222,060 |
| R. LaDuane Clifton CFO & Treasurer | Feb 13, 2025 | Sale(10b5-1 plan) | −11,000 | $7.86 | $86.46K | 51,361 |
| Joshua Schafer CCO & EVP, Bus. Development | Feb 13, 2025 | Sale(10b5-1 plan) | −10,500 | $7.86 | $82.53K | 29,486 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Feb 13, 2025 | Sale(10b5-1 plan) | −3,000 | $7.86 | $23.58K | 16,341 |
| Joshua Schafer CCO & EVP, Bus. Development | Jan 31, 2025 | Option exercise | +35,333 | – | – | 39,986 |
| R. LaDuane Clifton CFO & Treasurer | Jan 31, 2025 | Option exercise | +43,333 | – | – | 62,361 |
| Neil F. McFarlane President and CEO, Director | Jan 31, 2025 | Option exercise | +233,333 | – | – | 283,333 |
| Timothy J. Sangiovanni SVP, Finance & Corp Controller | Jan 31, 2025 | Option exercise | +11,666 | – | – | 19,341 |
| Corey Michael Watton Director | Oct 11, 2024 | Buy | +500 | $7.92 | $3.96K | 1,500 |
| R. LaDuane Clifton CFO & Treasurer | Jul 17, 2024 | Buy | +2,000 | $6.77 | $13.54K | 18,469 |
| Thomas Anderson Director | Jul 16, 2024 | Buy | +10,000 | $6.81 | $68.10K | 20,000 |
| John B. Bode Director | Jul 12, 2024 | Buy | +10,000 | $5.87 | $58.70K | 30,000 |
| R. LaDuane Clifton CFO, Secretary & Treasurer | Sep 6, 2023 | Buy | +1,000 | $4.96 | $4.96K | 15,309 |
| Thomas Anderson Director | Sep 6, 2023 | Buy | +10,000 | $4.88 | $48.80K | 10,000 |
| Joshua Schafer CCO & EVP, Bus. Development | Sep 5, 2023 | Buy | +500 | $5.13 | $2.57K | 3,500 |
| John B. Bode Director | Sep 5, 2023 | Buy | +10,000 | $5.13 | $51.30K | 20,000 |
| Corey Michael Watton Director | Jun 23, 2023 | Buy | +275 | $5.95 | $1.64K | 1,000 |
| Corey Michael Watton Director | Jun 9, 2023 | Buy | +325 | $5.52 | $1.79K | 725 |
| Corey Michael Watton Director | May 30, 2023 | Buy | +400 | $5.11 | $2.04K | 400 |
| Joshua Schafer CCO & EVP, Bus. Development | May 19, 2023 | Buy | +1,000 | $5.42 | $5.42K | 3,000 |
| John B. Bode Director | May 18, 2023 | Buy | +2,451 | $5.05 | $12.38K | 10,000 |
| John B. Bode Director | May 18, 2023 | Buy | +100 | $5.05 | $505 | 7,549 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Zevra Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 22,537 shares on Sep 8, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Neil F. McFarlane Director, Officer | Oct 13, 2026 | 20,000 | $227.80K | Oct 12, 2026 | Restricted Stock Units |
| Rahsaan Thompson Officer, Secretary | Aug 14, 2026 | 42,666 | $477.01K | Aug 14, 2026 | Restricted Stock Units |
| John B. Bode Director | Jul 8, 2026 | 10,516 | $156.16K | Jul 8, 2026 | Stock Option Exercise |
| Rahsaan Thompson Officer, Chief Legal & Compliance / Secretary | May 11, 2026 | 36,351 | $404.59K | May 11, 2026 | Restricted Stock Units |
| Raymond L Clifton Officer | Mar 16, 2026 | 345,428 | $3.41M | Mar 16, 2026 | Restricted stock vesting under a registered plan |
| Neil F. McFarlane Director, Officer | Feb 2, 2026 | 105,625 | $950.63K | Feb 2, 2026 | Restricted Stock Units |
| Adrian W. Quartel Officer | Jan 30, 2026 | 4,533 | $40.16K | Jan 30, 2026 | Restricted Stock Units |
| Joshua Schafer Officer | Jan 30, 2026 | 13,875 | $122.93K | Jan 30, 2026 | Restricted Stock Units |
| Rahsaan Thompson Officer, Secretary | Jan 30, 2026 | 4,080 | $36.15K | Jan 30, 2026 | Restricted Stock Units |
| R. LaDuane Clifton Former CFO & Treasurer | Jan 30, 2026 | 14,000 | $124.04K | Jan 30, 2026 | Restricted Stock Units |
| Timothy J. Sangiovanni Officer | Jan 30, 2026 | 4,750 | $42.09K | Jan 30, 2026 | Restricted Stock Units |
| Neil F. McFarlane Director, Officer | Oct 10, 2025 | 19,500 | $210.99K | Oct 10, 2025 | Restricted Stock Units |
| Rahsaan Thompson Officer, Secretary | Jun 26, 2025 | 24,000 | $223.92K | Jun 26, 2025 | Restricted Stock Units |
| Neil F. McFarlane Director, Officer | Feb 13, 2025 | 91,817 | $708.83K | Feb 13, 2025 | Restricted Stock Units |
| Joshua Schafer Officer | Feb 13, 2025 | 10,500 | $81.06K | Feb 13, 2025 | Restricted Stock Units |
See a number that looks wrong?